CN102548572A - 抗肺炎链球菌的疫苗和组合物 - Google Patents

抗肺炎链球菌的疫苗和组合物 Download PDF

Info

Publication number
CN102548572A
CN102548572A CN2010800388746A CN201080038874A CN102548572A CN 102548572 A CN102548572 A CN 102548572A CN 2010800388746 A CN2010800388746 A CN 2010800388746A CN 201080038874 A CN201080038874 A CN 201080038874A CN 102548572 A CN102548572 A CN 102548572A
Authority
CN
China
Prior art keywords
seq
polypeptide
bacterin preparation
nos
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800388746A
Other languages
English (en)
Chinese (zh)
Inventor
T·吉瑞
R·玛丽
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Genocea Biosciences Inc
Original Assignee
Boston Childrens Hospital
Genocea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital, Genocea Biosciences Inc filed Critical Boston Childrens Hospital
Priority to CN201710169055.9A priority Critical patent/CN107126557A/zh
Publication of CN102548572A publication Critical patent/CN102548572A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN2010800388746A 2009-06-29 2010-06-29 抗肺炎链球菌的疫苗和组合物 Pending CN102548572A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710169055.9A CN107126557A (zh) 2009-06-29 2010-06-29 抗肺炎链球菌的疫苗和组合物

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US22154109P 2009-06-29 2009-06-29
US61/221,541 2009-06-29
US24061609P 2009-09-08 2009-09-08
US24059809P 2009-09-08 2009-09-08
US61/240,616 2009-09-08
US61/240,598 2009-09-08
US31626710P 2010-03-22 2010-03-22
US61/316,267 2010-03-22
PCT/US2010/040406 WO2011008548A1 (en) 2009-06-29 2010-06-29 Vaccines and compositions against streptococcus pneumoniae

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201710169055.9A Division CN107126557A (zh) 2009-06-29 2010-06-29 抗肺炎链球菌的疫苗和组合物

Publications (1)

Publication Number Publication Date
CN102548572A true CN102548572A (zh) 2012-07-04

Family

ID=43449681

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010800388746A Pending CN102548572A (zh) 2009-06-29 2010-06-29 抗肺炎链球菌的疫苗和组合物
CN201710169055.9A Pending CN107126557A (zh) 2009-06-29 2010-06-29 抗肺炎链球菌的疫苗和组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201710169055.9A Pending CN107126557A (zh) 2009-06-29 2010-06-29 抗肺炎链球菌的疫苗和组合物

Country Status (15)

Country Link
US (2) US10105412B2 (enExample)
EP (1) EP2448592B1 (enExample)
JP (1) JP5931724B2 (enExample)
KR (1) KR101748453B1 (enExample)
CN (2) CN102548572A (enExample)
AU (1) AU2010273708B2 (enExample)
BR (1) BRPI1011919A2 (enExample)
CA (1) CA2803061A1 (enExample)
IL (1) IL217166A0 (enExample)
IN (1) IN2012DN00791A (enExample)
MX (1) MX2012000158A (enExample)
NZ (1) NZ597858A (enExample)
RU (1) RU2580299C2 (enExample)
SG (2) SG10201403702SA (enExample)
WO (1) WO2011008548A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201403702SA (en) 2009-06-29 2014-09-26 Genocea Biosciences Inc Vaccines and compositions against streptococcus pneumoniae
JP2013525271A (ja) 2010-03-12 2013-06-20 チルドレンズ メディカル センター コーポレーション 免疫原およびそのスクリーニング方法
JP6055780B2 (ja) * 2010-12-21 2016-12-27 マックス−プランク−ゲゼルシャフト ツール フェルデルンク デル ヴィッセンシャフテン エー．ファウ． 抗マイコバクテリアのワクチン接種の有効性の判定
MY163871A (en) * 2011-01-20 2017-10-31 Genocea Biosciences Inc Vaccines and compositions against streptococcus pneumoniae
UY33939A (es) * 2011-03-09 2012-09-28 Glaxosmithkline Llc Inhibidores de la péptido desformilasa
ES2864764T3 (es) 2011-05-11 2021-10-14 Childrens Medical Center Composición inmunogénica que presenta múltiples antígenos, y métodos y usos de la misma
EP2804627B1 (en) * 2012-01-20 2019-08-14 Genocea Biosciences Inc. Fused antigen vaccines and compositions against streptococcus pneumoniae
WO2014018904A1 (en) * 2012-07-26 2014-01-30 Genocea Biosciences, Inc. Fused antigen vaccines and compositions against streptococcus pneumoniae
EP4272750A3 (en) 2013-02-07 2024-01-24 Children's Medical Center, Corp. Protein antigens that provide protection against pneumococcal colonization and/or disease
US20150079132A1 (en) * 2013-09-17 2015-03-19 Path Evoking protection against streptotoccus pneumoniae incorporating b-cell and t-cell pneumococcal protein antigens and pneumococcal polysaccharides delivered concomitantly
EP3131579A4 (en) 2014-04-18 2017-10-25 The Children's Medical Center Corporation Vaccine adjuvant compositions
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
AU2018208844B2 (en) * 2017-01-20 2021-02-25 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
US11305001B2 (en) 2017-03-28 2022-04-19 The Children's Medical Center Corporation Multiple antigen presenting system (MAPS)-based Staphylococcus aureus vaccine, immunogenic composition, and uses thereof
CN111065417B (zh) 2017-06-23 2024-04-19 美商艾芬尼维克斯公司 免疫原性组合物
US12239702B2 (en) 2017-12-04 2025-03-04 Intervet Inc. Vaccination with replicon particles and oil adjuvant
PE20211112A1 (es) 2018-09-12 2021-06-22 Affinivax Inc Vacunas neumococicas multivalentes
SG11202101973YA (en) 2018-09-12 2021-03-30 Childrens Medical Ct Corp Pneumococcal fusion protein vaccines
RU2728938C1 (ru) * 2020-05-06 2020-08-03 Федеральное государственное бюджетное учреждение науки "Научный центр биомедицинских технологий Федерального медико-биологического агентства" (ФГБУН НЦБМТ ФМБА России) Применение даларгина для производства лекарственных средств профилактики пневмонии
WO2022013160A1 (en) 2020-07-16 2022-01-20 Henriques Normark Birgitta Streptococcal vaccines
WO2023039223A1 (en) 2021-09-09 2023-03-16 Affinivax, Inc. Multivalent pneumococcal vaccines

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018930A2 (en) * 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Streptococcus pneumoniae antigens and vaccines
WO2002077021A2 (en) * 2001-03-27 2002-10-03 Chiron Srl. Streptococcus pneumoniae proteins and nucleic acids
WO2004092209A2 (en) * 2003-04-15 2004-10-28 Intercell Ag S. pneumoniae antigens
US20050136404A1 (en) * 1997-07-02 2005-06-23 Doucette-Stamm Lynn A. Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics
US20060210580A1 (en) * 2000-10-27 2006-09-21 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from streptococcus groups A & B

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US5371197A (en) * 1991-09-24 1994-12-06 Merck & Co., Inc. Protein-dimeric polysaccharide conjugate vaccine
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
JP2000511769A (ja) 1996-04-02 2000-09-12 スミスクライン・ビーチャム・コーポレイション 新規化合物
CA2289116A1 (en) 1997-05-06 1998-11-12 Human Genome Sciences, Inc. Enterococcus faecalis polynucleotides and polypeptides
EP1009859A1 (en) 1997-06-20 2000-06-21 Human Genome Sciences Lyme disease vaccines
US5882885A (en) * 1997-07-17 1999-03-16 Smithkline Beecham Corporation Glycogen phosphorylase
US5994101A (en) * 1997-07-18 1999-11-30 Smithkline Beecham Corporation DNA encoding gidA1 polypeptides
US6617156B1 (en) * 1997-08-15 2003-09-09 Lynn A. Doucette-Stamm Nucleic acid and amino acid sequences relating to Enterococcus faecalis for diagnostics and therapeutics
US6248558B1 (en) 1998-03-31 2001-06-19 Vanderbilt University Sequence and method for genetic engineering of proteins with cell membrane translocating activity
WO2000006738A2 (en) 1998-07-27 2000-02-10 Microbial Technics Limited NUCLEIC ACIDS AND PROTEINS FROM $i(STREPTOCOCCUS PNEUMONIAE)
HK1043943A1 (zh) 1999-06-10 2002-10-04 Medimmune, Inc. 肺炎链球菌蛋白质和疫苗
US6887480B1 (en) * 1999-06-10 2005-05-03 Medimmune, Inc. Streptococcus pneumoniae proteins and vaccines
KR20020073150A (ko) * 1999-12-23 2002-09-19 브이맥스 리미티드 독성 유전자, 단백질, 및 그 용도
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
CA2444133A1 (en) * 2001-04-16 2002-10-24 Wyeth Holdings Corporation Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
US7314974B2 (en) * 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
EP2275128B1 (en) 2002-04-02 2013-10-16 Ben Gurion University Of The Negev Research And Development Authority Protein-based streptococcus pneumoniae vaccines
US20090252756A1 (en) * 2002-04-02 2009-10-08 Yaffa Mizrachi-Nebenzahl Protein-based streptococcus pneumoniae vaccines
WO2004018646A2 (en) 2002-08-26 2004-03-04 Chiron Corporation Conserved and specific streptococcal genomes
AU2003268353A1 (en) 2002-08-30 2004-03-19 Tufts University Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection
GB0318688D0 (en) * 2003-08-08 2003-09-10 Chiron Srl Streptococcus pneumoniae knockout mutants
EP1828231A2 (en) 2004-12-22 2007-09-05 Novartis Vaccines and Diagnostics, Inc. Group b streptococcus
WO2006084466A2 (en) * 2005-02-11 2006-08-17 Ace Biosciences A/S Surface-located streptococcus pneumoniae polypeptides
US20110177960A1 (en) * 2006-03-10 2011-07-21 Ellen Murphy Microarray for monitoring gene expression in multiple strains of Streptococcus pneumoniae
DK2054431T3 (da) * 2006-06-09 2012-01-02 Novartis Ag Konformere af bakterielle adhæsiner
GB0700136D0 (en) * 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
WO2008119358A2 (en) 2007-03-30 2008-10-09 Ace Biosciences A/S Surface-located streptococcus pneumoniae polypeptides for use in vaccine compositions
CN101855362A (zh) 2007-05-18 2010-10-06 美国政府健康及人类服务部，疾病控制和预防中心 用于检测肺炎链球菌的引物和探针
BRPI0811908A2 (pt) 2007-05-25 2014-11-18 Novartis Ag Antígenos de pilus de streptococcus pneumoniae
WO2008150885A1 (en) * 2007-05-29 2008-12-11 Board Of Regents, The University Of Texas System Modulation of the th-17 cell mediated immune responses
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
US20100278819A1 (en) * 2007-09-14 2010-11-04 Katholieke Universiteit Leuven Streptococcus pneumoniae vaccines
US7833776B2 (en) * 2007-12-12 2010-11-16 National Health Research Institutes Lipidating sequences and use thereof for producing lipidated proteins in E. coli
US8466259B2 (en) * 2007-12-07 2013-06-18 National Health Research Institutes Adjuvants
CA2717499A1 (en) * 2008-03-14 2009-09-17 Sanofi Pasteur Biologics Co. Replication-defective flavivirus vaccines and vaccine vectors
EP2300828B1 (en) 2008-07-01 2018-09-05 Genocea Biosciences Inc. Antigen screening system
US20110236470A1 (en) 2008-12-03 2011-09-29 Yaffa Mizrachi Nebenzahl GLUTAMYL tRNA SYNTHETASE (GtS) FRAGMENTS
US8287880B2 (en) * 2009-06-02 2012-10-16 National Health Research Institutes Lipidated vaccine against dengue virus infection
EP2445927B1 (en) * 2009-06-22 2014-04-23 National Health Research Institutes Lipidated tumor- associated antigens and immunotherapeutic compositions
US20120100172A1 (en) * 2009-06-25 2012-04-26 Michael Tal Immunogenic streptococcus pneumoniae peptides and peptide-multimers
SG10201403702SA (en) 2009-06-29 2014-09-26 Genocea Biosciences Inc Vaccines and compositions against streptococcus pneumoniae
WO2011064781A1 (en) 2009-11-30 2011-06-03 Ben-Gurion University Of The Negev Research And Development Authority S. pneumoniae adhesins
WO2011067758A2 (en) 2009-12-02 2011-06-09 Protea Vaccine Technologies Ltd. Immunogenic fragments and multimers from streptococcus pneumoniae proteins
JP5065434B2 (ja) * 2010-04-06 2012-10-31 株式会社日立製作所 管理方法及び管理装置
WO2011128892A2 (en) 2010-04-12 2011-10-20 Protea Vaccine Technologies Ltd. Modified forms of pneumococcal surface immunogenic protein b (psipb)
WO2011141968A1 (en) 2010-05-14 2011-11-17 Hitachi, Ltd. Storage apparatus and data retaining method for storage apparatus
MY163871A (en) * 2011-01-20 2017-10-31 Genocea Biosciences Inc Vaccines and compositions against streptococcus pneumoniae

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018930A2 (en) * 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Streptococcus pneumoniae antigens and vaccines
US20050136404A1 (en) * 1997-07-02 2005-06-23 Doucette-Stamm Lynn A. Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics
US20080175854A1 (en) * 1997-07-02 2008-07-24 Genome Therapeutics, Inc. Nucleic acid and amino acid sequences relating to streptococcus pneumoniae for diagnostics and therapeutics
US20060210580A1 (en) * 2000-10-27 2006-09-21 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from streptococcus groups A & B
WO2002077021A2 (en) * 2001-03-27 2002-10-03 Chiron Srl. Streptococcus pneumoniae proteins and nucleic acids
WO2004092209A2 (en) * 2003-04-15 2004-10-28 Intercell Ag S. pneumoniae antigens

Also Published As

Publication number Publication date
US20190298795A1 (en) 2019-10-03
WO2011008548A1 (en) 2011-01-20
EP2448592B1 (en) 2020-06-17
IN2012DN00791A (enExample) 2015-06-26
SG177402A1 (en) 2012-02-28
BRPI1011919A2 (pt) 2017-09-26
SG10201403702SA (en) 2014-09-26
KR20120093141A (ko) 2012-08-22
US11207375B2 (en) 2021-12-28
MX2012000158A (es) 2012-06-08
KR101748453B1 (ko) 2017-06-16
JP2012532134A (ja) 2012-12-13
JP5931724B2 (ja) 2016-06-08
EP2448592A1 (en) 2012-05-09
AU2010273708A8 (en) 2012-06-14
CN107126557A (zh) 2017-09-05
CA2803061A1 (en) 2011-01-20
AU2010273708A1 (en) 2012-02-23
RU2011153032A (ru) 2013-08-10
US10105412B2 (en) 2018-10-23
AU2010273708B2 (en) 2015-10-01
EP2448592A4 (en) 2013-04-24
NZ597858A (en) 2014-01-31
RU2580299C2 (ru) 2016-04-10
IL217166A0 (en) 2012-02-29
US20110020386A1 (en) 2011-01-27
WO2011008548A8 (en) 2012-03-08

Similar Documents

Publication Publication Date Title
US11207375B2 (en) Vaccines and compositions against Streptococcus pneumoniae
US10188717B2 (en) Vaccines and compositions against Streptococcus pneumoniae
KR20210088535A (ko) 폐렴구균 융합 단백질 백신
JP6379041B2 (ja) ストレプトコッカス・ニューモニエ（Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ）に対する融合抗原ワクチンおよび組成物
HK1172254A (en) Vaccines and compositions against streptococcus pneumoniae
HK1192166A (en) Vaccines and compositions against streptococcus pneumoniae
NZ614460B2 (en) Vaccines and compositions against streptococcus pneumoniae

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1172254

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20120704

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1172254

Country of ref document: HK